A Phase 1 Study to Assess Absolute Bioavailability of TAK-906 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Subjects
Latest Information Update: 09 Mar 2022
At a glance
- Drugs Trazpiroben (Primary) ; Trazpiroben (Primary)
- Indications Gastroparesis
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 14 Oct 2020 Status changed from recruiting to completed.
- 22 Sep 2020 Planned End Date changed from 15 Sep 2020 to 30 Sep 2020.
- 22 Sep 2020 Planned primary completion date changed from 15 Sep 2020 to 30 Sep 2020.